Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 13 | 2024 | 111 | 4.410 |
Why?
|
| Macrophages | 8 | 2022 | 439 | 2.750 |
Why?
|
| Reactive Oxygen Species | 5 | 2024 | 461 | 2.400 |
Why?
|
| Cytokines | 6 | 2022 | 602 | 2.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 48 | 1.890 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 34 | 1.770 |
Why?
|
| Carcinoma in Situ | 4 | 2017 | 12 | 1.750 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 935 | 1.730 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2022 | 12 | 1.580 |
Why?
|
| Protein Kinase C | 4 | 2016 | 120 | 1.560 |
Why?
|
| Metaplasia | 6 | 2024 | 37 | 1.330 |
Why?
|
| Pancreatic Ducts | 5 | 2017 | 5 | 1.160 |
Why?
|
| Cell Proliferation | 6 | 2020 | 1198 | 1.080 |
Why?
|
| Oxidative Stress | 2 | 2024 | 938 | 0.990 |
Why?
|
| Disease Progression | 4 | 2017 | 601 | 0.970 |
Why?
|
| Precancerous Conditions | 4 | 2019 | 82 | 0.870 |
Why?
|
| Signal Transduction | 9 | 2020 | 1908 | 0.850 |
Why?
|
| Pancreas | 4 | 2024 | 35 | 0.850 |
Why?
|
| Prostate | 2 | 2022 | 154 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 269 | 0.720 |
Why?
|
| Inflammation | 3 | 2024 | 618 | 0.710 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2020 | 56 | 0.670 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 169 | 0.660 |
Why?
|
| Animals | 19 | 2024 | 15081 | 0.620 |
Why?
|
| Prostatic Hyperplasia | 1 | 2018 | 34 | 0.620 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 78 | 0.620 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 103 | 0.610 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2018 | 99 | 0.610 |
Why?
|
| Genes, ras | 2 | 2014 | 25 | 0.600 |
Why?
|
| Interleukin-13 | 1 | 2017 | 19 | 0.590 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 213 | 0.570 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 123 | 0.560 |
Why?
|
| Mice | 11 | 2024 | 5913 | 0.550 |
Why?
|
| Neoplasms | 2 | 2020 | 1103 | 0.530 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 893 | 0.530 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 48 | 0.450 |
Why?
|
| Humans | 20 | 2024 | 37093 | 0.450 |
Why?
|
| Pancreas, Exocrine | 3 | 2017 | 3 | 0.440 |
Why?
|
| Cells, Cultured | 5 | 2020 | 1518 | 0.410 |
Why?
|
| Mitochondria | 1 | 2016 | 487 | 0.410 |
Why?
|
| Mutation | 2 | 2015 | 1095 | 0.370 |
Why?
|
| NF-kappa B | 1 | 2013 | 339 | 0.370 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 19 | 0.360 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 77 | 0.350 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 617 | 0.330 |
Why?
|
| Cell Line | 4 | 2020 | 1354 | 0.320 |
Why?
|
| Parkinson Disease | 1 | 2009 | 178 | 0.310 |
Why?
|
| Cell Transdifferentiation | 2 | 2017 | 8 | 0.280 |
Why?
|
| Pancreatitis | 2 | 2017 | 17 | 0.280 |
Why?
|
| Male | 8 | 2024 | 20025 | 0.270 |
Why?
|
| NF-kappa B p52 Subunit | 2 | 2016 | 5 | 0.250 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2024 | 16 | 0.240 |
Why?
|
| Chemokines, CC | 1 | 2024 | 51 | 0.230 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2016 | 188 | 0.220 |
Why?
|
| Up-Regulation | 2 | 2016 | 513 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 2231 | 0.210 |
Why?
|
| Osteopontin | 1 | 2022 | 36 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2017 | 172 | 0.200 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 433 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 109 | 0.180 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 85 | 0.170 |
Why?
|
| Thalidomide | 1 | 2019 | 5 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 807 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2019 | 45 | 0.160 |
Why?
|
| Prostatitis | 1 | 2018 | 1 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2024 | 642 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 219 | 0.150 |
Why?
|
| Neutralization Tests | 1 | 2017 | 53 | 0.150 |
Why?
|
| Cell Polarity | 1 | 2017 | 54 | 0.140 |
Why?
|
| Fibrosis | 1 | 2017 | 159 | 0.140 |
Why?
|
| Phenotype | 2 | 2017 | 689 | 0.140 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 68 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 197 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 1371 | 0.130 |
Why?
|
| NFATC Transcription Factors | 1 | 2015 | 6 | 0.130 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2015 | 22 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2015 | 10 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2014 | 22 | 0.130 |
Why?
|
| RNA Interference | 1 | 2016 | 243 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2015 | 33 | 0.120 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 40 | 0.120 |
Why?
|
| Ligands | 1 | 2016 | 349 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 1609 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 114 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2013 | 16 | 0.110 |
Why?
|
| Apoptosis | 1 | 2020 | 1398 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2012 | 16 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 93 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 661 | 0.100 |
Why?
|
| Phorbol Esters | 1 | 2010 | 8 | 0.090 |
Why?
|
| Leupeptins | 1 | 2010 | 11 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 22 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 131 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 201 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2010 | 102 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 803 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 859 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2009 | 928 | 0.070 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 32 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 251 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2017 | 933 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 358 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 623 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2005 | 681 | 0.050 |
Why?
|
| U937 Cells | 1 | 2019 | 27 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 15 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 9 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 132 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 174 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 399 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 571 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 356 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 27 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 674 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 172 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.030 |
Why?
|
| Agar | 1 | 2013 | 8 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 36 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2013 | 60 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1742 | 0.030 |
Why?
|
| Thiazoles | 1 | 2013 | 74 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2013 | 366 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 435 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 972 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1015 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 384 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 37 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 47 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 90 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 122 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 150 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2005 | 150 | 0.020 |
Why?
|
| Cadherins | 1 | 2005 | 90 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 325 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 127 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 251 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 128 | 0.020 |
Why?
|
| Transfection | 1 | 2005 | 523 | 0.020 |
Why?
|
| Prognosis | 1 | 2005 | 739 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1369 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1207 | 0.010 |
Why?
|
| Aged | 1 | 2005 | 6741 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 10129 | 0.010 |
Why?
|
| Female | 1 | 2005 | 20969 | 0.000 |
Why?
|